| Literature DB >> 35791431 |
Bhagyashri Chaudhari1, Harun Patel2, Snehal Thakar1, Iqrar Ahmad2, Deepali Bansode1.
Abstract
Sunitinib is a potent anti-cancer scaffold that acts as a VEGFR-2 inhibitor. Although the scaffold exhibits potent anti-cancer activity, it is cardiotoxic and also induces hypothyroidism. The current research aims to optimize the Sunitinib for cardio-toxicity and thyro-toxicity by scaffold hopping approach using the admetSAR server. The server has optimized the physico-chemical properties of Sunitinib, which were contributing to the cardiotoxicity and thyro-toxicity. The library of the optimized compounds was further screened by the molecular docking studies and results were validated by the MD simulation and DFT analysis for VEGFR-2 inhibition. Compounds 163 and 432 exhibited the highest affinity to VEGFR-2 receptor with minimal cardiotoxicity and thyro-toxicity. These two compounds could be the starting point for the further discovery of angiogenic inhibitors. Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-022-00125-1.Entities:
Keywords: Cardiotoxicity; Docking; Sunitinib; Thyro-toxicity; VEGFR-2
Year: 2022 PMID: 35791431 PMCID: PMC9250587 DOI: 10.1007/s40203-022-00125-1
Source DB: PubMed Journal: In Silico Pharmacol ISSN: 2193-9616